-
The second wave of COVID19 outbreak is coming, and a few tips to help you stay healthy
Time of Update: 2020-10-31
the arrival of autumn and winter can lead to an increased risk of common cold symptoms, and when we cough or sneeze, it is recommended to look for shelter in advance, such as bending your elbows or covering your mouth and nose with a hand towel.
-
Mol Cell: Special small RNA molecules play a key role in helicobacter pyridosis infecting humans
Time of Update: 2020-10-31
In this study, researchers found for the first time that the expression of small RNA molecules, such as NikS (not just proteins), is also affected by phase variation, which can be beneficial depending on the condition in the host's stomach, and that levels of small RNA molecules can be adapted to this condition by bit phase variation, which can lead to different regulation of pathogenic factors.
-
Multiple articles focus on the close relationship between gut microbiotics and the occurrence of multiple human diseases!
Time of Update: 2020-10-31
in recent years, there has been more and more research evidence that the body's gut microbiome is directly related to the occurrence of a variety of human diseases. FILE PHOTO: scitecheuropa.eu Cell
-
Devel Cell: Chemotherapy preparations may have the opposite effect on the overgrowth of normal tissues in the body
Time of Update: 2020-10-31
22, 2020 // -- In a recent study published in the international journal Developmental Cell, scientists from Vanderburg University and other institutions reported an intuitive finding that specific che
-
Want to effectively prevent infection and transmission of COVID-19? These 12 best preventive strategies may help you!
Time of Update: 2020-10-31
5) Cautious eating out Although many restaurants offer outdoor dining services to diners, which experts say is safe, a recent study from the CDC in the United States found that adults infected with COVID-19 were twice as likely to eat in restaurants as adults who were not infected in the two weeks before the disease, and the study did not distinguish between indoor or outdoor dining, while the researchers also considered the social distance and mouth of the population.
-
New drugs for special dermatitis! AbbVie Rinvoq submits new adaptation applications in the U.S. and Europe to treat adult and adolescent patients!
Time of Update: 2020-10-31
Oct 22, 2020 // -- AbbVie recently announced that it has submitted a new application for Rinvoq (upadacitinib) to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), a drug Selective, reversible JAK inhibitors for the treatment of adult patients with moderate to severe idiopathic dermatitis (atopic dermatitis, AD) (15mg and 30mg once daily) and adolescent patients (15mg, once daily).
-
Why are men more likely to develop COVID-19?
Time of Update: 2020-10-31
According to previous studies, there appears to be no significant difference between men and women in the risk of SARS-coV-2 infection, but the risk of severe illness and death is significantly higher in men.
-
Nat Commun: Scientists have successfully developed a deep learning model tool that could better predict the outcome of lung cancer
Time of Update: 2020-10-31
October 22, 2020 // -- Over the past 20 years, the development and choice of individualized therapies for lung cancer patients has come a long way, with non-small cell lung cancer remaining the leadin
-
How important is blood type to the health of the body? Look at the results!
Time of Update: 2020-10-31
Photo credit: medicalxpress.com.au Blood Adv: Using blood type or promising to help predict an individual's risk of contracting severe COVID-19 doi:10.1182/bloodadvances.20 In two studies published in the international journal Blood Advances before 20002623, scientists from the University of British Columbia and other institutions found that blood type may affect a person's risk of COVID-19 and the resulting serious disease.
-
Respiratory syncytial virus (RSV) vaccine! GSK Maternal Vaccine and Senior Vaccine Clinical Research: Rapidly Induce Strong Immunity!
Time of Update: 2020-10-31
() Original origin: GSK presents positive clinical data on maternal and older adults RSV candidate vaccines
-
Progress in Parkinson's disease research is at a glance.
Time of Update: 2020-10-30
DOI:10.1073/pnas.2003021117 In a recent study published in the international journal Proceedings of the National Academy of Sciences, scientists from institutions such as McLean Hospital found that lipid changes in a class of key brain cells may play a key role in inflammation and Parkinson's disease, and the results are expected to help develop new treatments for Parkinson's disease.
-
Sci Adv: Scientists find dangerous T-cells in the body's pancreatic tissue or hopefully reveal new mechanisms for type 1 diabetes!
Time of Update: 2020-10-30
Photo Source: Von Herrath Laboratory, La Jolla Institute for Immunology previously believed that T cells with autologn reactions in the pancreas were the exact sign of type 1 diabetes, but in this study, researchers found that even in healthy people's pancreatic tissue, there may be a large number of such cells, autolognical reactive T cells.
-
BMJ: Groundbreaking Test! Regulatory T-cell transplantation is expected to overcome immunosuppression of organ transplantation.
Time of Update: 2020-10-29
and Andy Roemhild and others published a research paper online in BMJ, the world's top medical journal, entitled "Regulatory T cells for minimising immune suppression in kidneyation: phase I/IIa clinical trial", a single-center, nTreg dose Incremental, I/IIa Phase Clinical Trials (ONEnTreg13), Recipients of Live Supply Kidney Transplants (ONEnTreg13, n s 11) and corresponding reference group trials (ONErgt11-CHA, n s 9).
-
Isaipe, 50% national price reduction
Time of Update: 2020-10-29
Due to the early launch time, Isep gained a first-mover advantage, dominated the domestic TNF-α inhibitor market, and also became the absolute revenue of Sansheng Guojian, according to the previously announced prospecto, 2017-201 In august, Isepp achieved sales of 1,094 million, 1,128 million and 1,162 million, respectively, accounting for 100%, 100% and 99.84% of the company's operating income.
-
The theme report of the 4th Psoriasis Conference is brilliant, focusing on the frontiers and development of psoriasis.
Time of Update: 2020-10-29
The team of the Institute of Dermatology of Anhui Medical University discovered the psoriasis coding mutation susceptible gene IL-23 through genome-wide exon sequencing, so as to develop the targeted biological agent Gusechiyu monoantigen, which showed good effectiveness and safety in the treatment of psoriasis, with a high clinical response rate and significantly improved the quality of life of psoriasis patients.
-
ESID 2020: Sensitivity analysis confirms the efficacy of Emapalumab in treating phage lymphocytosis (HLH).
Time of Update: 2020-10-28
sensitivity analysis of phase II/III key studies (NCT01818492) presented at the 19th meeting of the European Society of Immunodeficiency (ESID), a pharmaceutical company, showed that the total remission rate (ORR) was as high as 63% for HLH patients who did not respond to standard therapies.
sensitivity analysis supports the use of clinical objective ORR as the primary endpoint in primary HLH studies.
-
Gastroenterology: Diet and Crohn's disease risk.
Time of Update: 2020-10-28
recently analyzed data from three large prospective cohorts to determine the effects of underlying inflammatory factors in the diet on crohn's disease (CD) and ulcerative colitis (UC) risk.
study found that a diet with a high inflammatory risk increased participants' risk of Crohn's disease, but was not associated with a risk of ulcerative colitis.
-
TREMFYA (guselkumab) treatment of active psoriasis arthritis (PsA): positive advice has been received from CHMP.
Time of Update: 2020-10-28
Active psoriasis arthritis (PsA) is a chronic, immuno-mediated inflammatory disease characterized by joint damage and inflammation in addition to dermatitis, mastitis, axon disease and psoriasis-related skin lesions.
Guselkumab is currently approved in the European Union for the treatment of systemic moderate to severe plaque-like psoriasis.
-
Gastroenterology: Study on the correlation between celiac disease and the risk of inflammatory bowel disease.
Time of Update: 2020-10-28
evidence of low certainty increased the positive risk of anti-yeast antibodies (serological markers of IBD) in CeD patients (RR:6.22) compared to the control group.
systematic review and meta-analysis showed a link between celiac disease and inflammatory bowel disease, with an increased risk of developing one disease.
-
Phase III data prove that IL-23 monoantigen TREMFYA can maintain skin removal rate in patients with plaque psoriasis for 5 consecutive years.
Time of Update: 2020-10-28
Johnson and Johnson announced new open label extension data for its Phase III clinical study VOYAGE 1, which showed that after nearly five years of treatment with TREMFYA (guselkumab), adult patients with moderate to severe plaque psoriasis consistently maintained high skin removal rates with no new safety signals.